Comparative study on the efficacy of pioglitazone in Caucasian and Maori-Polynesian patients with poorly controlled type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 9, Issue 4, 2007, Pages 540-547

  Shand, Brett ^a   Scott, S ^a   Connolly, S ^a   Clarke, R ^b   Baker, J ^b   Elder, P ^c   Frampton, C ^a   Yeo, J ^c  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b MIDDLEMORE HOSPITAL   (New Zealand)

^c CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

Adiponectin; Caucasians; Dyslipidaemia; Ethnicity; Maori Polynesians; Pioglitazone; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; HEMOGLOBIN A1C; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADD ON THERAPY; ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BODY WEIGHT; CARDIOVASCULAR RISK; CAUCASIAN; CHI SQUARE TEST; CLINICAL STUDY; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DIABETES CONTROL; DRUG DOSE INCREASE; DRUG EFFICACY; EDEMA; ETHNIC GROUP; ETHNICITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOTHESIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MAORI; MAXIMUM TOLERATED DOSE; METABOLISM; MONOTHERAPY; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PACIFIC ISLANDER; PATIENT SELECTION; PILOT STUDY; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

EID: 34347395961     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00635.x     Document Type: Article

References (23)

1. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002; 25: 517-23.
2. Bell DSH. β-cell rejuvenation with thiazolidinediones. Am J Med 2003; 115: 20S-23S.
3. Dormandy JA, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
4. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus. Drugs 2003; 63: 1373-1405.
5. Simmons D. The epidemiology of diabetes and its complications in New Zealand. Diabet Med 1996; 13: 371-75.
6. Simmons D, Thompson CF, Volklander D. Maori-Polynesians: Prone to obesity and Type 2 diabetes mellitus but not hyperinsulinaemia. Diabet Med 2001; 18: 193-198.
7. Simmons D, Gatland BA, Leakehe L, Fleming C. Ethnic differences in diabetes care in a multiethnic community in New Zealand. Diab Res Clin Pract 1996; 34 (Suppl.): S89-S93.
8. Moore MP, Lunt H. Diabetes in New Zealand. Diab Res Clin Pract 2000; 50 (Suppl. 2): S65-S71.
9. Dagogo-Jack S. Ethnic disparities in type 2 diabetes: Pathophysiology and implications for prevention and management. J Natl Med Assoc 2003; 95: 779-789.
10. Wagstaff AJ, Goa KL. Rosiglitazone: A review of its use in the management of type 2 diabetes mellitus. Drugs 2002; 62: 1805-1837.
11. Statistics New Zealand. New Zealand Census of Population and Dwellings 2001.
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without any use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-509.
13. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982; 23: 97-104.
14. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER HDL). Clin Biochem 2001; 34: 583-588.
15. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12: 413-423.
16. Winkler K, Friedrich I, Nauck M, Wieland H, Maerz W. Pioglitazone reduces dense LDL-particles in patients with type-2 diabetes. Diabetes 2001; 50 (Suppl. 2): A147.
17. King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 2000; 23: 557.
18. Ikeda H, Sugiyama Y. Pharmacological effects of a thiazolidinedione derivative, pioglitazone (abstract). Nippon Rinsho - Japanese J Clin Med 2001; 59: 2191-2194.
19. Smith U. Pioglitazone: Mechanism of action. Int J Clin Pract 2001; 121 (Suppl.): 13-18.
20. Pfutzner A, Marx N, Lubben G et al. Improvement of cardiovascular risk factors by pioglitazone is independent from glycemic control: Results from the pioneer study. J Am Coll Cardiol 2005; 45: 1925-1931.
21. King AB, Armstrong DU. Lipid response to pioglitazone in diabetic patients: Clinical observations from a retrospective chart review. Diabetes Technol Ther 2002; 4: 145-151.
22. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51: 2968-2974.
23. Yang B, Brown KK, Chen L et al. Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats. BMC Pharmacol 2004; 4: 23.